# Lauric acid reduces apoptosis by inhibiting FOXO3a-signaling in deoxynivalenol-treated IPEC-J2 cells

Na Yeon Kim[1], Sang In Lee[1,2]*

[1]Department of Animal Science and Biotechnology, Kyungpook National University, Sangju 37224, Korea
[2]Research Institute for Innovative Animal Science, Kyungpook National University, Sangju 37224, Korea

*Corresponding author
Sang In Lee
Department of Animal Science and Biotechnology, Kyungpook National University, Sangju 37224, Korea.
Tel: +82-54-530-1943
E-mail: silee78@knu.ac.kr

ORCID
Na Yeon Kim
https://orcid.org/0009-0004-2727-1246
Sang In Lee
https://orcid.org/0000-0002-0019-1834

Abstract

Deoxynivalenol (DON) is the most common mycotoxin contaminant of food or feed worldwide and causes disease in animals. Lauric acid (LA) is a medium-chain fatty acid useful for barrier functions such as antimicrobial activity in the intestine of monogastric animals. However, the molecular mechanisms by which lauric acid exerts its effects on the deoxynivalenol-exposed small intestine have not been studied. We used an intestinal porcine epithelial cell line (IPEC-J2) as an *in vitro* model to explore the molecular mechanism of lauric acid in alleviating deoxynivalenol-induced damage. We found that lauric acid reversed deoxynivalenol-induced reduction in cell viability. Our quantitative real-time polymerase chain reaction results indicated that lauric acid alleviated deoxynivalenol-induced apoptosis through Annexin-V. Additionally, immunofluorescence and Western blotting showed that lauric acid attenuated deoxynivalenol-induced forkhead box O3 (FOXO3a) translocation into the nucleus. These results suggest that lauric acid attenuates forkhead box O3 translocation in the small intestine damaged by deoxynivalenol, thereby reducing apoptosis. In conclusion, this study found that lauric acid alleviates deoxynivalenol-induced damage in intestinal porcine epithelial cell line through various molecular mechanisms.

Keywords: Intestinal porcine epithelial cell line (IPEC-J2 cells), Deoxynivalenol, Lauric acid, Apoptosis, Foxo3a

INTRODUCTION

The intestinal epithelium digests and absorbs nutrients and forms a barrier against pathogens and toxic substances [1,2]. The intestinal epithelium is also important for maintaining health as it is the first physical barrier to detect external substances [3]. Damage to the intestinal epithelium disrupts immune homeostasis, increases inflammation, disrupts its function as a barrier and leads to many intestinal diseases, including pathogenic infections [4,5]. The intestinal epithelium is constantly exposed to bacteria, fungi, viruses, and parasites that can act as pathogens [6]. The intestinal epithelium is exposed to higher concentrations of mycotoxins than other organs, thus, it is the first to suffer toxic damage [7,8]. Exposure of the intestinal epithelium to mycotoxins disrupts its function as a barrier through

Authors' contributions
Conceptualization: Lee SI.
Data curation: Kim NY, Lee SI.
Formal analysis: Kim NY, Lee SI.
Methodology: Kim NY, Lee SI.
Validation: Kim NY, Lee SI.
Writing - original draft: Kim NY, Lee SI.
Writing - review & editing: Kim NY, Lee SI.

disrupted intestinal integrity (physical), thinned mucus layer (chemical), imbalanced inflammatory factors (immunological), and dysfunctional bacterial homeostasis (microbial) [8].

Deoxynivalenol (DON) is a mycotoxin produced by *Fusarium* species and contaminates food and feed worldwide [9]. DON mainly contaminates crops such as maize, wheat, and barley and exposure to it poses a health threat to both humans and animals [10]. Pigs are the most susceptible animals to DON [11]. After eating DON-contaminated feed, they suffer from anorexia, vomiting, diarrhea, and deterioration of their immune and reproductive functions [12]. Additionally, DON affects growth and weight gain rate, and causes stiff pig syndrome, abortion, stillbirth, and weak offspring [13]. Current methods to reduce exposure to mycotoxins include thermal processing, chemical agents, and toxin binders [14]. However, these methods do not completely destroy mycotoxins, and toxin binders change their nutritional value and reduce bioavailability of trace minerals or vitamins [15]. Therefore, research on other natural products that can alleviate mycotoxins is required.

Lauric aci (LA) is a medium-chain fatty acid (MCFA) composed of 12 carbon atoms and is found in coconut oil, milk, and black soldier flies (BSF, *Hermetia illucens* L.) [16,17]. MCFAs, including LA, influence nutritional functions, digestion, absorption, and energy supply in monogastric intestines, while also regulating immune responses, relieving stimulus-induced symptoms, and contributing to barrier functions [18–20]. Therefore, LA, one of MCFAs, can be used as an inexpensive and new feed additive to replace antibiotics [20,21]. Nevertheless, the molecular mechanisms by which LA benefit the mycotoxin-damaged small intestine epithelium are unknown and require further study. Therefore, in this study, we investigated the molecular mechanism of LA in mitigating DON-induced dysfunction in porcine small intestinal epithelium using IPEC-J2 cells.

MATERIALS AND METHODS

Cell culture and treatment
IPEC-J2 cells (DSMZ, Braunschweig, Germany) isolated from unsuckling piglet jejunal epithelium were cultured in Dulbecco's Modified Eagle Medium (Thermo Fisher Scientific, Wilmington, DE, USA) supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin in a 37℃ CO_2 incubator. Lauric acid (Sigma-Aldrich, St. Louis, MO, USA) was diluted with dimethyl sulfoxide for treating IPEC-J2 cells.

Cell viability
IPEC-J2 cells were seeded in 3×10^4 cells in a 96-well plate, cultured for 24 h, before they were exposed to LA (0, 0.1, 0.2, 0.3, 0.4, and 0.5 mM) or LA (0.2 mM) and DON (0.25 μg) for 24 h. After 2 h of treatment with Water-Soluble Tetrazolium 1 (WST-1) (Roche Diagnostics GmbH, Mannheim, Germany), cell viability was measured by analyzing the absorbance of the dye by subtracting the background wavelength from 450 nm to 600 nm using a GloMax Discover Multi-Microplate Reader. And Cell viability was compared to control group and was calculated by converting absorbance to percentage.

Annexin-V and propodiumiodide stainings
After 24 h of LA and DON treatment, IPEC-J2 cells were harvested, washed with phosphate-buffered saline (PBS), and centrifuged. After discarding the supernatant, 1X Annexin binding buffer 5 μL Alexa Fluor 488 Annexin-V (Thermo Fisher Scientific), and 1 μL 100 mg/mL propidium iodide (PI) working solution were added. After incubation of the cells at room

temperature for 15 min in the dark, the nucleus was stained with 4',6-diamidino-2-phenylindole (DAPI;Vector Laboratories, Burlingame, CA, USA) and mounted on a slide using a coverslip. Pictures of the cells were taken using a fluorescence microscope (Korealabtech, Seongnam, Korea).

Immunofluorescence staining of cells

IPEC-J2 cells treated with LA and DON were grown on gelatin-coated glass cover slips for 24 h before they were fixed with 4% paraformaldehyde for 15 min. After that, the cells were treated with a blocking buffer for 1 h. Rabbit anti-forkhead box O3 (FOXO3a) IgG was treated with a 1:200 antibody solution and probed overnight. After washing with PBS three times for 3 min, goat antirabbit (488) (Thermo Fisher Scientific, Carlsbad, CA, USA) was treated with the antibody solution at a ratio of 1:500 and incubated for 1 h in the dark. Thereafter, the nucleus was stained with DAPI (Vector Laboratories) covered with a cover slip, the cells were photographed under a fluorescence microscope.

Extraction of cytoplasmic and nuclear proteins

Cytoplasmic and nuclear proteins were extracted using NE-PER Nuclear and Cytoplasmic Extraction Reagent (Thermo Fisher Scientific) according to the manufacturer's instructions. Cells were washed with chilled PBS and centrifuged at 500×g for 3 min. After discarding the supernatant, cytoplasmic extraction reagent I (CERI) was added to the cell pellet, vortexed for 15 s before the suspension was incubated on ice for 10 min. Cytoplasmic extraction reagent II (CERII) was added and vortexing for 15 s, the mixture was incubated on ice for 1 min. After centrifugation of the suspension at 16,000×g, the cytoplasmic extraction suspension was transferred to a prechilled tube. A nuclear extraction reagent (NER) was added to the insoluble pellet before vortexing for 15 s every 10 min for a total of 40 min. After centrifugation at 16,000×g for 10 min, the supernatant was transferred into a prechilled tube. The extracted protein was analyzed for protein concentration using the Pierce Bicinchoninic acid (BCA) Protein Assay Kit (Thermo Fisher Scientific). The extracted proteins were used in subsequent analyses.

Western blotting

Protein samples were denatured in 4X Laemmli buffer (4% sodium dodecyl sulfate, 10% 2-mercaptoethanol, 20% glycerol, 0.004% bromophenol blue, and 0.125 M Tris-HCl) (3:1) at 95°C for 5 min. Proteins were electrophoretically separated on 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels (run for 1 h at 100 V) before they were transferred to polyvinylidene fluoride membranes (Thermo Fisher Scientific). After blocking for 2 h, the proteins were treated with anti-FOXO3a (Novus Biologicals, Centennial, CO, USA) antibody overnight. The membrane was washed three times with Tris-buffered saline containing Tween 20 (TBST, 20 mM Tris, pH 7.5, 150 mM NaCl and 0.1% Tween 20) for 10 min before it was treated with a secondary antibody for 1 h at room temperature. Protein bands were visualized for immunoreactivity using the Enhanced Chemiluminescence (ECL) reagent, and protein bands were imaged using the ChemiDoc imaging system.

Real-time polymerase chain reaction

Total RNA extraction was performed using the AccuPreP Universal RNA Extraction kit (BioNEER, Daejeon, Korea). cDNA was synthesized from total RNA (1 μg) using the DiaStar™ RT Kit (SolGent, Daejeon, Korea). Primer 3 (http://frodo.wi.mit.edu) was used to design primers for target genes in qPCR. For qRT-PCR, 40 cycles of 95℃ for 3 min, 95℃ for 15 sec, 56℃−58℃ for 15 sec, and 72℃ for 15 s were used. Levels of target genes were calculated using the $2^{-\Delta\Delta Ct}$

method, normalized to glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*). The primer sequences of the genes are shown in Table 1.

Statistical analysis

The general linear model (PROC-GLM) procedure in SAS was used to test for significant differences between treatment groups. Fig.1B Data were analyzed using *t*-tests. Symbols of significance were set as **$p < 0.01$, ***$p < 0.001$. For other cell viability and PCR data were evaluated for significant differences between treatment groups using Duncan's multiple range test. All experiments were performed independently in triplicate.

RESULTS

Lauric acid affects cell proliferation in IPEC-J2 cells

To confirm the cell viability of LA for IPEC-J2 cells, the cell proliferation analysis WST-1 assay was performed. IPEC-J2 cells were exposed to LA at different concentrations (0, 0.1, 0.2, 0.3, 0.4, and 0.5 mM); Concentrations of 0.1–0.2 mM of LA increased cell proliferation whereas LA at concentrations of 0.3 mM or higher decreased cell proliferation (Fig. 1A). Therefore, LA concentration of 0.2 mM was chosen for further analyses. The effect of 0.2 mM LA on IPEC-J2 cells was time dependents cell proliferation increased at 24, 48, 72, and 96 h (Fig. 1B). Accordingly, we used 24 h for further analyses. Cell viability was compared between all treated and control groups by converting absorbance values into percentages as shown in the figure.

Lauric acid affects deoxynivalenol-induced cell proliferation in IPEC-J2 cells

We used the cell proliferation analysis WST-1 assay to assess whether LA affects cell proliferation capacity induced by DON. IPEC-J2 cells treated with DON showed significantly lower cell proliferation than those in the control. However, we observed that when DON-treated IPEC-J2 cells were co-treated with LA, cell proliferation increased (Fig. 2), indicating that LA alleviates DON-induced reduction in cell proliferation capacity.

Lauric acid alleviates deoxynivalenol-induced apoptosis and necrosis in IPEC-J2 cells

To determine whether LA alleviates DON-induced apoptosis and necrosis in IPEC-J2 cells,

Table 1. List of primers

| Genes	Description	Accession No.		Sequence (5'-3')
GAPDH	Glyceraldehyde-3-phosphate dehydrogenase	NM_001206359	Forward	ACACCGAGCATCTCCTGACT
			Reverse	GACGAGGCAGGTCTCCCTAA
FOXO3	Fork headbox O3	NM_001135959	Forward	TCAGCCAGTCTATGCAAACC
			Reverse	CCATGAGTTCGCTACGGATA
CASP3	Caspase 3	NM_214131	Forward	CTCAGGGAGACCTTCACAAC
			Reverse	GCACGCAAATAAAACTGCTC
CASP9	Caspase 9	XM_013998997.2	Forward	TACCCTGCCTTACCTTCCAC
			Reverse	CTGGTCTTCGGTCATCTGG
BCL-2	BCL2 apoptosis regulator	XM_021099593.1	Forward	AAAGCCACAAGGAGAAAAGC
			Reverse	TTCAGCCACCGTAAAATCTG
BCL-6	B-cell CLL/lymphoma 6	XM_005657112	Forward	GTGTCCTACGGTGCCTTTTT
			Reverse	TGACGCAGAATGTGATGAGA

Fig. 1. Lauric acid (LA) promotes IPEC-J2 cells proliferation at 0.1, 0.2 mM, and decreases the cell viability at the concentration of 0.4 mM or higher. (A) The WST-1 assay of the IPEC-J2 cells after exposure to 0–0.5mM LA for 24 H (n = 3). Error bars indicated SE of triplicate analysis. Lowercase letters ($^{a-d}$) mean significant differences between groups based on Duncan's multi-range test.(B) The WST-1 assay of IPEC-J2 cells on treatment with 0.2 mM for 24 h, 48 h, 72 h, and 96 h, compared to untreated control (n = 3). Error bars indicated standard error (SE) of triplicate analysis. ***p < 0.001.


Fig. 2. Lauric acid (LA) improves IPEC-J2 cells proliferation dysfunction by deoxynivalenol (DON)-induced. The WST-1 assay of IPEC-J2 cell treated with only DON, and DON + LA compared to untreated control for 24 h (n = 3). $^{a-c}$Significant differences between control and treatment groups are indicated by different letters ($^{a-c}$) with p < 0.05. DON, deoxynivalenol; LA, lauric acid.

we performed double staining with Annexin-V and propidium iodide. Apoptosis and necrosis were significantly increased in IPEC-J2 cells treated with DON. In contrast, when IPEC-J2 cells exposed to DON were treated with LA, apoptosis and necrosis were reduced (Fig. 3A). Additionally, when examining the mRNA expression levels of apoptosis-related genes such as *Bcl–2*, *Bcl–6*, *CASP3*, and *CASP9*, the mRNA expression was significantly lower when cells were exposed to both LA and DON than to DON alone. Moreover, the mRNA expression of *FOXO3a* was also higher in cells exposed to DON than in those in the control and decreased when cells were treated with LA (Fig. 3B)., indicating that LA alleviates DON-induced apoptosis and necrosis.

Lauric acid attenuates deoxynivalenol-induced FOXO3a translocation to the nucleus

Annexin-V results showed that LA alleviated DON-induced apoptosis and necrosis. We hypothesized that this might be influenced by FOXO3a signaling. Therefore, we measured the expression of FOXO3a protein in IPEC-J2 cells using immunocytochemistry, Western blotting, and real-time PCR. Immunocytochemistry results showed that DON-induced FOXO3a nuclear translocation was similar to that of the control. However, DON-induced FOXO3a nuclear

Fig. 3. Lauric acid (LA) mitigates apoptosis and necrosis in IPEC-J2 cells. (A) The apoptosis in IPEC-J2 cells treated with DON and LA + DON compared to untreated control for 48h analyzed by Annexin V staining. Apoptosis analysis was performed by single cell staining using Annexin-V (green) and propidium (red) iodide, and nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI; blue). (Scale bar means 20 μm). The arrow indicates that only apoptosis was induced, and the triangle indicates that both apoptosis and necrosis were induced. (B) The mRNA levels of apoptosis-related genes (*FOXO3a*, *BCL2*, *BCL6*, *CASP3*, *CASP9*) were compared with those of the control when treated with DON alone and with DON and LA (*n*=3). Error bars indicated standard error (SE) of triplicate analysis. [a–c]Significant differences between control and treatment groups are indicated as a, b and c, with *p*<0.05 indicating the significance level. PI, propidium iodide; DON, deoxynivalenol; LA, lauric acid.


Fig. 4. Lauric acid (LA) attenuates deoxynivalenol (DON)-induced FOXO3a expression and translocation. (A) FOXO3a translocation was evaluated using immunocytochemistry. Nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI; blue). (Scale bar means 40 μm). (B) FOXO3a translocation was evaluated using Western blotting. DON, deoxynivalenol; LA, lauric acid.

Fig. 5. Schematic diagram of the current working hypothesis that lauric acid (LA) to mitigate deoxynivalenol (DON)-mediated apoptosis through the FOXO3a signaling pathway. (A) Model illustration showing DON-induced FOXO3a translocation, which induces apoptosis by regulating *BCL-2* and *BCL-6* expression and sequentially inducing activation of *CASP9* and *CASP3*. (B) Model illustration describing that LA attenuates DON-induced FOXO3a translocation, thereby reducing cell death. DON, deoxynivalenol; LA, lauric acid.

translocation was attenuated in cells co-treated with DON and LA (Fig. 4A). Additionally, Western blotting results showed that the expression of FOXO3a was significantly decreased in the cytoplasm and significantly increased in the nucleus of DON-treated IPEC-J2 cells. In contrast, in IPEC-J2 cells co-treated with LA and DON, the expression of FOXO3a significantly increased in the cytoplasm and significantly decreased in the nucleus (Fig. 4B).

DISCUSSION

DON is a mycotoxin that causes various symptoms such as anorexia, vomiting, and stunted growth, leading to poor health and economic loss [22]. The intestine is the first biological barrier to mycotoxins because it is the first target of exposure after consuming contaminated food [23,24]. Intestinal exposure to DON causes symptoms such as destruction of intestinal epithelial cells, impairment of integrity of intestinal barrier, destruction of tight junction protein structures, increased intestinal epithelial permeability, reduced nutrient absorption and transport efficiency, inflammation, and induction of apoptosis [25]. To reduce exposure to mycotoxins, various methods such as toxin binders are used, but they are not completely effective [14,15]. LA is a MCFA that promotes intestinal health through its effects such as antibacterial activity, reduction of inflammatory response, and reduction of oxidative stress [18,26]. Previous studies have shown that LA has beneficial effects on the intestine through its antibacterial activity [27–29]. Therefore, LA can be used as a new feed additive to replace antibiotics. Thus, we speculated that LA would alleviate DON-induced damage to the small intestine epithelial cells.

First, we investigated the cytotoxicity of various concentrations of LA to IPEC-J2 cells. The WST-1 assay showed that LA concentrations of 0.1 and 0.2 mM had a beneficial effect on cell proliferation. However, there was no statistically significant difference between 0.1 and 0.2 mM in cell viability. Therefore, further analyses were conducted using an LA concentration of 0.2 mM. In a previous study, when IPEC-J2 cells were exposed to DON at a concentration of 250 ng/mL, cell proliferation was significantly lower than that of the control group [30]. Therefore, we decided to use DON at a concentration of 250 ng/mL for further analyses. We observed that cell proliferation was significantly higher in cells co-exposed with LA at 0.2 mM and DON than in cells exposed only to DON 0.25 ug/mL.

Apoptosis is a highly regulated cell death process induced by various stimuli such as mycotoxins

and unfavorable physiological conditions, which can damage the intestinal epithelium and lead to intestinal pathology [31–33]. Reduced cell proliferation is associated with increased apoptosis [34,35]. Therefore, we speculated that cell proliferation reduced by DON and increased when treated with LA might also be related to apoptosis. FOXO3a induces apoptosis by inhibiting the apoptosis-inhibitor protein [36]. It also induces the expression of several proapoptotic members, including *Bcl-2* and *Bcl-6*, to inhibit cell growth and promote apoptotic signaling [33,37]. Expression of these proapoptotic proteins catalyzes the activation of the initiator caspase (caspase-9), which in turn activates the effector factor (caspase-3) [38,39]. Activated caspase-3 causes morphological changes in apoptotic cells [39]. For example, caspase-3 cleavage of caspase-activated DNAse (ICAD) initiates activation of caspase-activated DNAse (CAD). The activation of CAD then cleaves the DNA at the inter-nucleosome linker sites, leading to chromatin condensation and DNA fragmentation [40,41]. This form of DNA fragmentation is a common characteristic of cells undergoing apoptosis. In addition, *Bcl-2* is overexpressed to prevent cell death in the early stages of necrotic activation [42]. Our RT-PCR results showed that the mRNA expression of *FOXO3a* was increased in cells exposed to DON but decreased in those exposed LA. Also, genes related to apoptosis such as *Bcl-2*, *Bcl-6*, *CASP3*, and *CASP9* were increased by DON and decreased by LA relative to the control group. Additionally, we observed that LA alleviated DON-induced apoptosis and necrosis through Annexin-V staining. Therefore, our findings confirmed that LA mitigated DON-induced apoptosis and necrosis in IPEC-J2 cells.

The forkhead box O (FOXO) protein activates or inhibits the transcription of target genes through its DNA-binding foxo domain in the nucleus via the nucleocytoplasmic shuttle, and regulates cell cycle arrest, DNA repair and apoptosis, stress, and tumor suppressor pathways [43]. FOXO family members of the Forkhead transcription factor include Foxo1, Foxo3, Foxo4, and Foxo6 [44]. Among several FOXO family members, FOXO3a is abundant in various tissues including the brain, heart, kidney, and spleen and is the most important transcription factor involved in apoptosis and cell cycle inhibition [33,43]. Upon intestinal exposure to factors such as mycotoxin, FOXO3a protein translocates from the nucleocytoplasm to the nucleus to form DNA-binding foxo domains, triggering apoptosis and leading to intestinal damage (Fig. 5A). Our immunocytochemistry and Western blotting analysis showed that DON treatment induced nuclear translocation of FOXO3a protein. In contrast, DON-induced nuclear translocation of FOXO3a protein was attenuated when cells were co-treated with DON and LA (Fig. 5B). Our results show that LA reversed the increase in apoptosis caused by DON-induced nuclear translocation of the FOXO3a protein in IPEC-J2 cells.

This study is the first to investigate the effect of LA on DON-treated porcine intestinal epithelial cells. Our findings indicated that LA alleviated DON-induced reduction in cell proliferation and DON-induced increase in apoptosis (Figs. 5A and 5B). This suggests that LA has a beneficial effect on DON-induced damage to the intestinal epithelium. Additionally, our results suggest that LA can be used as a natural antibiotic in the future.

REFERENCES

1. Yang H, Xiong X, Wang X, Tan B, Li T, Yin Y. Effects of weaning on intestinal upper villus epithelial cells of piglets. PLOS ONE. 2016;11:e0150216. https://doi.org/10.1371/journal.pone.0150216

2. Jang HJ, Lee SI. MicroRNA expression profiling during the suckling-to-weaning transition in pigs. J Anim Sci Technol. 2021;63:854-63. https://doi.org/10.5187/jast.2021.e69

3. Kang R, Li R, Dai P, Li Z, Li Y, Li C. Deoxynivalenol induced apoptosis and inflammation of

IPEC-J2 cells by promoting ROS production. Environ Pollut. 2019;251:689-98. https://doi.org/10.1016/j.envpol.2019.05.026

4. Yi H, Hu W, Chen S, Lu Z, Wang Y. Cathelicidin-WA improves intestinal epithelial barrier function and enhances host defense against enterohemorrhagic Escherichia coli O157:H7 infection. J Immunol. 2017;198:1696-705. https://doi.org/10.4049/jimmunol.1601221

5. Mun D, Kyoung H, Kong M, Ryu S, Jang KB, Baek J, et al. Effects of Bacillus-based probiotics on growth performance, nutrient digestibility, and intestinal health of weaned pigs. J Anim Sci Technol. 2021;63:1314-27. https://doi.org/10.5187/jast.2021.e109

6. Gallo RL, Hooper LV. Epithelial antimicrobial defence of the skin and intestine. Nat Rev Immunol. 2012;12:503-16. https://doi.org/10.1038/nri3228

7. Ren Z, Guo C, Yu S, Zhu L, Wang Y, Hu H, et al. Progress in mycotoxins affecting intestinal mucosal barrier function. Int J Mol Sci. 2019;20:2777. https://doi.org/10.3390/ijms20112777

8. Gao Y, Meng L, Liu H, Wang J, Zheng N. The compromised intestinal barrier induced by mycotoxins. Toxins. 2020;12:619. https://doi.org/10.3390/toxins12100619

9. Zhang C, Zhang KF, Chen FJ, Chen YH, Yang X, Cai ZH, et al. Deoxynivalenol triggers porcine intestinal tight junction disorder: insights from mitochondrial dynamics and mitophagy. Ecotoxicol Environ Saf. 2022;248:114291. https://doi.org/10.1016/j.ecoenv.2022.114291

10. Liao S, Tang S, Tan B, Li J, Qi M, Cui Z, et al. Chloroquine improves deoxynivalenol-induced inflammatory response and intestinal mucosal damage in piglets. Oxid Med Cell Longev. 2020;2020:9834813. https://doi.org/10.1155/2020/9834813

11. García GR, Payros D, Pinton P, Dogi CA, Laffitte J, Neves M, et al. Intestinal toxicity of deoxynivalenol is limited by Lactobacillus rhamnosus RC007 in pig jejunum explants. Arch Toxicol. 2018;92:983-93. https://doi.org/10.1007/s00204-017-2083-x

12. Wang S, Yang J, Zhang B, Wu K, Yang A, Li C, et al. Deoxynivalenol impairs porcine intestinal host defense peptide expression in weaned piglets and IPEC-J2 cells. Toxins. 2018;10:541. https://doi.org/10.3390/toxins10120541

13. Yao Y, Long M. The biological detoxification of deoxynivalenol: a review. Food Chem Toxicol. 2020;145:111649. https://doi.org/10.1016/j.fct.2020.111649

14. Čolović R, Puvača N, Cheli F, Avantaggiato G, Greco D, Đuragić O, et al. Decontamination of mycotoxin-contaminated feedstuffs and compound feed. Toxins. 2019;11:617. https://doi.org/10.3390/toxins11110617

15. Hussein HS, Brasel JM. Toxicity, metabolism, and impact of mycotoxins on humans and animals. Toxicology. 2001;167:101-34. https://doi.org/10.1016/S0300-483X(01)00471-1

16. Yang Y, Huang J, Li J, Yang H, Yin Y. The effects of lauric acid on IPEC-J2 cell differentiation, proliferation, and death. Curr Mol Med. 2020;20:572-81. https://doi.org/10.2174/1566524020666200128155115

17. Surendra KC, Tomberlin JK, van Huis A, Cammack JA, Heckmann LHL, Khanal SK. Rethinking organic wastes bioconversion: evaluating the potential of the black soldier fly (Hermetia illucens (L.)) (Diptera: stratiomyidae) (BSF). Waste Manag. 2020;117:58-80. https://doi.org/10.1016/j.wasman.2020.07.050

18. Jia M, Zhang Y, Gao Y, Ma X. Effects of medium chain fatty acids on intestinal health of monogastric animals. Curr Protein Pept Sci. 2020;21:777-84. https://doi.org/10.2174/1389203721666191231145901

19. Lauridsen C. Effects of dietary fatty acids on gut health and function of pigs pre- and post-weaning. J Anim Sci. 2020;98:skaa086. https://doi.org/10.1093/jas/skaa086

20. Jackman JA, Boyd RD, Elrod CC. Medium-chain fatty acids and monoglycerides as feed additives for pig production: towards gut health improvement and feed pathogen mitigation. J

Anim Sci Biotechnol. 2020;11:44. https://doi.org/10.1186/s40104-020-00446-1

21. Zheng C, Chen Z, Yan X, Xiao G, Qiu T, Ou J, et al. Effects of a combination of lauric acid monoglyceride and cinnamaldehyde on growth performance, gut morphology, and gut microbiota of yellow-feathered broilers. Poult Sci. 2023;102:102825. https://doi.org/10.1016/j.psj.2023.102825

22. Vandenbroucke V, Croubels S, Martel A, Verbrugghe E, Goossens J, Van Deun K, et al. The mycotoxin deoxynivalenol potentiates intestinal inflammation by Salmonella typhimurium in porcine ileal loops. PLOS ONE. 2011;6:e23871. https://doi.org/10.1371/journal.pone.0023871

23. Chen J, Huang Z, Cao X, Chen X, Zou T, You J. Plant-derived polyphenols as Nrf2 activators to counteract oxidative stress and intestinal toxicity induced by deoxynivalenol in swine: an emerging research direction. Antioxidants. 2022;11:2379. https://doi.org/10.3390/antiox11122379

24. Yoon JW, Lee SI. Gene expression profiling after ochratoxin a treatment in small intestinal epithelial cells from pigs. J Anim Sci Technol. 2022;64:842-53. https://doi.org/10.5187/jast.2022.e49

25. Tang M, Yuan D, Liao P. Berberine improves intestinal barrier function and reduces inflammation, immunosuppression, and oxidative stress by regulating the NF-κB/MAPK signaling pathway in deoxynivalenol-challenged piglets. Environ Pollut. 2021;289:117865. https://doi.org/10.1016/j.envpol.2021.117865

26. Tham YY, Choo QC, Muhammad TST, Chew CH. Lauric acid alleviates insulin resistance by improving mitochondrial biogenesis in THP-1 macrophages. Mol Biol Rep. 2020;47:9595-607. https://doi.org/10.1007/s11033-020-06019-9

27. Wu Y, Zhang H, Zhang R, Cao G, Li Q, Zhang B, et al. Serum metabolome and gut microbiome alterations in broiler chickens supplemented with lauric acid. Poult Sci. 2021;100:101315. https://doi.org/10.1016/j.psj.2021.101315

28. Zeng X, Yang Y, Wang J, Wang Z, Li J, Yin Y, et al. Dietary butyrate, lauric acid and stearic acid improve gut morphology and epithelial cell turnover in weaned piglets. Anim Nutr. 2022;11:276-82. https://doi.org/10.1016/j.aninu.2022.07.012

29. Liu Z, Xie W, Zan G, Gao C, Yan H, Zhou J, et al. Lauric acid alleviates deoxynivalenol-induced intestinal stem cell damage by potentiating the Akt/mTORC1/S6K1 signaling axis. Chem Biol Interact. 2021;348:109640. https://doi.org/10.1016/j.cbi.2021.109640

30. Wang X, Zhang Y, Zhao J, Cao L, Zhu L, Huang Y, et al. Deoxynivalenol induces inflammatory injury in IPEC-J2 Cells via NF-κB signaling pathway. Toxins. 2019;11:733. https://doi.org/10.3390/toxins11120733

31. Xu X, Lai Y, Hua ZC. Apoptosis and apoptotic body: disease message and therapeutic target potentials. Biosci Rep. 2019;39:BSR20180992. https://doi.org/10.1042/BSR20180992

32. Negroni A, Cucchiara S, Stronati L. Apoptosis, necrosis, and necroptosis in the gut and intestinal homeostasis. Mediators Inflamm. 2015;2015:250762. https://doi.org/10.1155/2015/250762

33. Kang TH, Kang KS, Lee SI. Deoxynivalenol induces apoptosis via FOXO3a-signaling pathway in small-intestinal cells in pig. Toxics. 2022;10:535. https://doi.org/10.3390/toxics10090535

34. Leard LE, Broaddus VC. Mesothelial cell proliferation and apoptosis. Respirology. 2004;9:292-9. https://doi.org/10.1111/j.1440-1843.2004.00602.x

35. Zhao W, Zhang X, Zhou Z, Sun B, Gu W, Liu J, et al. Liraglutide inhibits the proliferation and promotes the apoptosis of MCF-7 human breast cancer cells through downregulation of microRNA-27a expression. Mol Med Rep. 2018;17:5202-12. https://doi.org/10.3892/

mmr.2018.8475

36. Hagenbuchner J, Ausserlechner MJ. Mitochondria and FOXO3: breath or die. Front Physiol. 2013;4:147. https://doi.org/10.3389/fphys.2013.00147

37. Melnik BC. Apoptosis may explain the pharmacological mode of action and adverse effects of isotretinoin, including teratogenicity. Acta Derm Venereol. 2017;97:173-81. https://doi.org/10.2340/00015555-2535

38. Brunet A, Datta SR, Greenberg ME. Transcription-dependent and -independent control of neuronal survival by the PI3K–Akt signaling pathway. Curr Opin Neurobiol. 2001;11:297-305. https://doi.org/10.1016/S0959-4388(00)00211-7

39. Eskandari E, Eaves CJ. Paradoxical roles of caspase-3 in regulating cell survival, proliferation, and tumorigenesis. J Cell Biol. 2022;221:e202201159. https://doi.org/10.1083/jcb.202201159

40. Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature. 1998;391:43-50. https://doi.org/10.1038/34112

41. Larsen BD, Sørensen CS. The caspase-activated DNase: apoptosis and beyond. FEBS J. 2017;284:1160-70. https://doi.org/10.1111/febs.13970

42. Nikoletopoulou V, Markaki M, Palikaras K, Tavernarakis N. Crosstalk between apoptosis, necrosis and autophagy. Biochim Biophys Acta Mol Cell Res. 2013;1833:3448-59. https://doi.org/10.1016/j.bbamcr.2013.06.001

43. Zhang X, Tang N, Hadden TJ, Rishi AK. Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta Mol Cell Res. 2011;1813:1978-86. https://doi.org/10.1016/j.bbamcr.2011.03.010

44. Snoeks L, Weber CR, Turner JR, Bhattacharyya M, Wasland K, Savkovic SD. Tumor suppressor Foxo3a is involved in the regulation of lipopolysaccharide-induced interleukin-8 in intestinal HT-29 cells. Infect Immun. 2008;76:4677-85. https://doi.org/10.1128/IAI.00227-08